trending Market Intelligence /marketintelligence/en/news-insights/trending/d9feksyctz7pjhtxclgzla2 content esgSubNav
In This List

Seres Therapeutics adds former Novartis executive to board

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Seres Therapeutics adds former Novartis executive to board

Cambridge, Mass.-based biotechnology company Seres Therapeutics Inc. appointed Meryl Zausner as a board member.

Zausner previously served as chief financial and administrative officer of Novartis AG unit Novartis Pharmaceuticals Corp. and a member of the U.S. pharmaceutical executive committee and global finance leadership team.

Seres Therapeutics develops medicines using live bacteria to treat diseases resulting from functional deficiencies of microorganisms within the body.